D. Boral Capital Reaffirms Buy Rating for NeuroSense Therapeutics (NASDAQ:NRSN)

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock.

Separately, D Boral Capital raised NeuroSense Therapeutics to a “strong-buy” rating in a research report on Monday, May 12th.

NeuroSense Therapeutics Stock Down 1.9%

Shares of NeuroSense Therapeutics stock opened at $2.07 on Thursday. The firm’s 50 day moving average price is $1.78 and its 200-day moving average price is $1.32. NeuroSense Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.60. The company has a market cap of $28.30 million, a P/E ratio of -3.83 and a beta of 1.66.

Institutional Trading of NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Jane Street Group LLC purchased a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 64,636 shares of the company’s stock, valued at approximately $78,000. Jane Street Group LLC owned about 0.47% of NeuroSense Therapeutics at the end of the most recent quarter. 1.04% of the stock is owned by institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.